Clinical trials: ADPKD
Autosomal Dominant Polycystic Kidney Disease
Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD
The purpose of this study is to determine whether patients with autosomal dominant polycystic kidney disease (ADPKD) present with abnormal endothelial function, increased levels of NOX4 activity and mitochondrial abnormalities…
- Trial name
- NCT03493802
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Polycystic Kidney, Autosomal Dominant
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02494141
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Colorado, Denver
ADPKD
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
This is a retrospective analysis to include demographic, clinical, biochemical, and genetic data that will further explore the natural history of ADPKD and assess the factors that are likely to be associated with the progression…
- Trial name
- ADPKD (NCT02161068)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- The Rogosin Institute
Autosomal Dominant Polycystic Kidney Disease
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening).
- Trial name
- NCT01022424
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Autosomal Dominant Polycystic Kidney
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
The study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Oral AL01211 in healthy volunteers
- Trial name
- NCT04908462
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- AceLink Therapeutics, Inc.
Polycystic Kidney, Autosomal Dominant
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria.
- Trial name
- STOP-PKD (NCT07280585)
- Testing
- Dapagliflozin 10 mg
- Where
- 30 sites in Austria, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- University of Cologne
Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are…
- Trial name
- AGAINST-PLD (NCT05478083)
- Testing
- Leuprorelin
- Where
- 2 sites in Netherlands
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Autosomal Dominant Polycystic Kidney, ADPKD
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD.
- Trial name
- FALCON (NCT03918447)
- Testing
- Bardoxolone methyl oral capsule
- Where
- 137 sites in United States, Australia and 8 more
- Volunteers
- 667 people
- Sponsor
- Biogen
Autosomal Dominant Polycystic Kidney
Outcome of ADPKD With Octreotide LAR
In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chronic GFR decline and other…
- Trial name
- ADPKD648 (NCT06193616)
- Testing
- Octreotide
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Kidney Disease, Autosomal Dominant
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
Primary Objective To assess the dose response relationship between RGLS4326 and ADPKD biomarkers Secondary Objectives To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine To assess the safety and…
- Trial name
- NCT04536688
- Testing
- RGLS4326
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Regulus Therapeutics Inc.
Autosomal Dominant Polycystic Kidney, ADPKD
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
This is a Phase 3 trial consisting of a 2-arm, double-blind, placebo-controlled, randomized phase (Part 1) followed by a single-arm open-label phase (Part 2) to demonstrate the efficacy and safety of lixivaptan in participants…
- Trial name
- ACTION (NCT04064346)
- Testing
- Lixivaptan
- Where
- 43 sites in United States, Australia and 6 more
- Volunteers
- 12 people
- Sponsor
- Palladio Biosciences
Polycystic Kidney Diseases
Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).
Pathological features of Autosomal Dominant Polycystic Kidney disease (ADPKD) include enlarged kidney volume, a higher frequency of digestive diverticulitis and abdominal wall hernias.
- Trial name
- ADPKDPD (NCT03948113)
- Testing
- Dialysis
- Where
- France
- Volunteers
- 17,350 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Autosomal Dominant Polycystic Kidney
Thyroid Hormones in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic, rare and life-threatening disease, characterized by the pathological formation of multiple fluid-filled cysts that arise from renal tubules and alter kidney…
- Trial name
- REORIENTED (NCT05646420)
- Testing
- Blood sampling
- Where
- Italy
- Volunteers
- 91 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease, Hypertension
Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
A randomized, open-label single-center study investigates the efficacy and safety of bilateral renal artery sympathetic denervation by catheter-based radiofrequency ablation on blood pressure and disease progression control in…
- Trial name
- RAFALE (NCT01932450)
- Testing
- renal sympathetic denervation, antihypertensive drugs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mei changlin
Autosomal Dominant Polycystic Kidney Disease
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant Polycystic Kidney…
- Trial name
- NCT03487913
- Testing
- Lixivaptan
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Palladio Biosciences
ADPKD
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
The investigators are running a study to see if a special drink, called a "ketone ester", can help people with a type of kidney disease named "Autosomal Dominant Polycystic Kidney Disease" or ADPKD for short.
- Trial name
- ADKETONE (NCT06100133)
- Testing
- Ketone ester
- Volunteers
- 20 people
- Sponsor
- Universitair Ziekenhuis Brussel
Autosomal Dominant Polycystic Kidney, Overweight and Obesity
Daily Caloric Restriction in ADPKD
This clinical trial will determine whether a daily-caloric restriction-based weight loss intervention can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese.
- Trial name
- NCT04907799
- Testing
- Daily caloric restriction, Standard advice control
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney Disease
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common single gene disorder that is potentially fatal. ADPKD is caused by mutations in either of two genes (PKD1, PKD2).
- Trial name
- NCT00759369
- Testing
- Water prescription
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Kansas
Polycystic Kidney Disease, Assisted Reproductive Technology
Descriptive Analysis of Preimplantation Genetic Test (PGT)in Couples With Polycystic Kidney Disease (PKD). In the ADPKD Subgroup Evaluation of Outcomes and Complications Comparing Couples in Which the Father is Affected With Couples in Which the Mother is Affected
The goal of this observational study is to evaluate the outcomes of assisted reproductive technology (ART) combined with preimplantation genetic testing for monogenic diseases (PGT-M) in couples affected by or carriers of…
- Conditions
- Polycystic Kidney Disease, Assisted Reproductive Technology, Preimplantation Genetic Testing (PGT)
- Trial name
- PGT-M PKD (NCT07310641)
- Testing
- Assisted reproductive technology and preimplantation diagnosis for monogenic diseases
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Azienda Sanitaria Universitaria Integrata del Trentino
Polycystic Kidney, Autosomal Dominant
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or…
- Trial name
- NCT01233869
- Testing
- Bosutinib
- Where
- 67 sites in United States, Australia and 15 more
- Volunteers
- 172 people
- Sponsor
- Pfizer